We are live on
!
Find out more
Federated Hermes Portfolio holdings
AUM
$69.6B
1-Year Est. Return
42.52%
This Fund
S&P 500
This Quarter
Est. Return
+1.34%
1 Year Est. Return
+42.52%
3 Year Est. Return
+132.48%
5 Year Est. Return
+152.58%
10 Year Est. Return
+652.43%
AUM
$42.2B
AUM Growth
-$1.23B
(-2.8%)
Cap. Flow
-$952M
Cap. Flow
% of AUM
-2.26%
Top 10 Holdings %
Top 10 Hldgs %
14.57%
Holding
2,171
New
150
Increased
772
Reduced
960
Closed
152
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$156M |
| 2 |
Prologis
PLD
|
+$150M |
| 3 |
Chevron
CVX
|
+$109M |
| 4 |
Qualcomm
QCOM
|
+$101M |
| 5 |
Paycom
PAYC
|
+$90.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
+$230M |
| 2 |
Kimberly-Clark
KMB
|
+$160M |
| 3 |
Stanley Black & Decker
SWK
|
+$130M |
| 4 |
Paychex
PAYX
|
+$113M |
| 5 |
Dominion Energy
D
|
+$105M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.81% |
| 2 | Healthcare | 17.11% |
| 3 | Financials | 12.73% |
| 4 | Industrials | 9.87% |
| 5 | Consumer Discretionary | 9.74% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1401
Bioceres Crop Solutions
BIOX
$24.6M
| – | – |
0
| – | – |
|
1402
FormFactor
FORM
$8.19B
| $319K | ﹤0.01% |
5,272
+445
| +9% | +$23.2K |
|
|
ACLX
1403
DELISTED
Arcellx
ACLX
| $316K | ﹤0.01% |
5,733
-225,928
| -98% | -$12.3M |
|
1404
Alector
ALEC
$215M
| $311K | ﹤0.01% |
68,538
+2,709
| +4% | +$13.9K |
|
1405
First Bancorp
FBNC
$2.59B
| $310K | ﹤0.01% |
9,724
-365
| -4% | -$11.6K |
|
1406
Blackstone
BX
$92.7B
| $310K | ﹤0.01% |
2,504
-963
| -28% | -$119K |
|
1407
AdaptHealth
AHCO
$788M
| $309K | ﹤0.01% |
30,901
+101
| +0.3% | +$1.03K |
|
1408
Las Vegas Sands
LVS
$26.6B
| $307K | ﹤0.01% |
6,940
+198
| +3% | +$9.24K |
|
|
TGNA
1409
DELISTED
TEGNA Inc
TGNA
| $305K | ﹤0.01% |
21,882
-3,590
| -14% | -$50.6K |
|
1410
Gold Fields
GFI
$37.4B
| $302K | ﹤0.01% |
20,293
-2,750
| -12% | -$44.7K |
|
1411
Associated Banc-Corp
ASB
$5.62B
| $301K | ﹤0.01% |
14,235
-3,632
| -20% | -$76.5K |
|
1412
Canadian Natural Resources
CNQ
$103B
| $297K | ﹤0.01% |
8,352
+1,862
| +29% | +$70.1K |
|
1413
Coda Octopus Group
CODA
$121M
| $297K | ﹤0.01% |
49,221
| – | – |
|
1414
Polaris
PII
$3.15B
| $296K | ﹤0.01% |
3,786
-486
| -11% | -$41.2K |
|
1415
Ziff Davis
ZD
$2.01B
| $296K | ﹤0.01% |
5,377
-153
| -3% | -$8.42K |
|
1416
International Bancshares
IBOC
$4.41B
| $293K | ﹤0.01% |
5,118
-232
| -4% | -$13.1K |
|
1417
OSI Systems
OSIS
$3.22B
| $290K | ﹤0.01% |
+2,110
| New | +$291K |
|
1418
SOPHiA GENETICS
SOPH
$678M
| $289K | ﹤0.01% |
63,000
+23,000
| +58% | +$112K |
|
|
SILK
1419
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $288K | ﹤0.01% |
10,664
+9,663
| +965% | +$201K |
|
1420
Relmada Therapeutics
RLMD
$450M
| $288K | ﹤0.01% |
96,010
| – | – |
|
|
AMED
1421
DELISTED
Amedisys
AMED
| $287K | ﹤0.01% |
3,130
-164
| -5% | -$15.2K |
|
|
UNIT
1422
Uniti Group
UNIT
$2.32B
| $287K | ﹤0.01% |
98,256
-994,212
| -91% | -$4.17M |
|
1423
Triumph Financial Inc
TFIN
$1.52B
| $286K | ﹤0.01% |
3,504
+264
| +8% | +$19.7K |
|
1424
Intapp
INTA
$2.83B
| $286K | ﹤0.01% |
7,805
+694
| +10% | +$23.6K |
|
1425
Federated Hermes
FHI
$4.23B
| $278K | ﹤0.01% |
8,449
-1,075
| -11% | -$36.1K |
|
Similar funds
Federated Hermes's Q2 2024 Portfolio in Review
As of Q2 2024, Federated Hermes held 2,171 positions worth $42.2B, down 2.8% from $43.4B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Federated Hermes's Q2 2024 filing shows 150 new, 772 increased, 960 reduced and 152 closed positions. Its largest new stake was Loar Holdings: 729,296 shares worth $39M. The largest sale was Fusion Pharmaceuticals Inc. Common Shares, an estimated $230M.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 17% a quarter earlier, followed by Healthcare and Financials.
- Federated Hermes's largest Q2 2024 buy was Loar Holdings: 729,296 shares worth $39M.
- Federated Hermes added most to Bristol-Myers Squibb in Q2 2024, an estimated $156M increase.
- Federated Hermes's biggest Q2 2024 reduction was Kimberly-Clark, cutting an estimated $160M.
- Federated Hermes fully exited Fusion Pharmaceuticals Inc. Common Shares in Q2 2024, selling an estimated $230M.
- Federated Hermes's ten largest holdings make up 15% of its $42.2B portfolio in Q2 2024.
- Federated Hermes opened 150 new positions and closed 152 in Q2 2024.
- Federated Hermes's portfolio value fell 2.8% quarter-over-quarter to $42.2B.
Based on Federated Hermes's 13F filing for Q2 2024, filed 8 Aug 2024.